SCHEMBL3978628

SCHEMBL3978628

CCc1ccc(NS(=O)(=O)c2cccs2)c(C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.67
MCL1 Q07820 1/20 0.63
BCL2A1 Q16548 1/20 0.63
ALDH1A1 P00352 5/20 0.51
LMNA P02545 2/20 0.48
RECQL P46063 1/20 0.48
MAPT P10636 1/20 0.47
GAA P10253 1/20 0.47
MEN1 O00255 1/20 0.47
BRAF P15056 1/20 0.47
KMT2A Q03164 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979169 0.81 METAP2 (1.00) METAP2MCL1BCL2A1ALDH1A1GAA
SCHEMBL711338 0.78 MCL1 (0.63) MCL1BCL2A1ALDH1A1GAAMEN1
SCHEMBL18152031 0.78 MCL1 (1.00) MCL1BCL2A1
SCHEMBL2738020 0.77 METAP2 (0.70) METAP2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3982510 0.77 METAP2 (0.59) METAP2ALDH1A1LMNAMAPTMEN1
SCHEMBL3983978 0.77 METAP2 (0.73) METAP2MCL1BCL2A1ALDH1A1MAPT
SCHEMBL3980105 0.76 METAP2 (0.81) METAP2MCL1ALDH1A1LMNAHTT
SCHEMBL3986786 0.76 METAP2 (0.71) METAP2MCL1BCL2A1ALDH1A1MAPT
SCHEMBL3981500 0.76 METAP2 (0.71) METAP2MCL1BCL2A1ALDH1A1LMNA
SCHEMBL3982602 0.76 METAP2 (0.79) METAP2MCL1BCL2A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.